Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Early visual outcome of LASIK correction by using combination of iFS advanced femtosecond laser and new advanced CustomVue technology for myopia: an Asian perspective

Poster Details

First Author: S.Ganesan MALAYSIA

Co Author(s):                  

Abstract Details


To assess visual outcome and stability of LASIK patients who underwent a combination treatment of iFS Advanced Femtosecond Laser and Star S4 IR Excimer Laser with idesign Advanced WaveScan Studio.


Single site study, single surgeon at VISTA Eye Specialist, Malaysia.


This is a non-randomized prospective study. Exclusion criteria include large corneal scars, full thickness corneal laceration scars, advanced glaucoma, small fixed pupils, cornea ectasia and peculiar corneal findings. 60 eyes of 30 patients were evaluated in this study. The mean age of enrolled patients was 26.4 ±6.2, (Range 20-35). All patients undergone idesign Advanced WaveScan device during pre-operative. Flaps were created with the iFS Advanced Femtosecond Laser followed by Star S4 IR Excimer Laser for refractive correction. The uncorrected visual acuity (UCVA) was taken during 1 day, 1week and 1 month after surgery. Best corrected visual acuity (BCVA) and residual refractive error were taken during 1 month post-operative.


The pre-operative mean refractive spherical equivalent (MRSE) was -5.74 ±2.44D. The UCVA results were 0.96 ±0.16, 88.3% achieved 20/25 or better at 1 day post-operative visit, 0.95 ±0.18, 88.3% achieved 20/25 or better at 1 week and 1.00 ±0.16, 91.7% achieved 20/25 or better at 1 month. At 1 month post-operative, the MRSE was -0.07 ±0.23D and BCVA was 1.02 ±0.14.


There was an excellent outcomes and quick visual recovery of LASIK patients underwent combination treatment of iFS Advanced Femtosecond Laser & Advanced CustomVue Technology for the correction of myopia and astigmatism. Financial Disclosure: I do not have any financial interest in AMO.

Financial Disclosure:


Back to previous